Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 5 (2008), Issue 1 (January)

1. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia.
   Oncogene, 27(1): 98-106. [Abstract] [Full-text]
2. Pantoea agglomerans bacteremia in a 65-year-old man with acute myeloid leukemia: case report and review.
   South Med J, 101(1): 102-3. [Abstract] [Full-text]
3. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
   Cancer, 112(2): 407-15. [Abstract] [Full-text]
4. Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing hematopoietic stem cell transplantation.
   Pediatr Blood Cancer, 50(3): 673-6. [Abstract] [Full-text]
5. Presentation of acute promyelocytic leukemia as granulocytic sarcoma.
   Pediatr Blood Cancer, 50(3): 657-60. [Abstract] [Full-text]
6. Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
   Pediatr Blood Cancer, 50(3): 651-4. [Abstract] [Full-text]
7. Acute myelogenous leukemia associated with Ollier disease.
   Pediatr Blood Cancer, 50(3): 645-6. [Abstract] [Full-text]
8. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
   Eur J Haematol, 80(2): 115-26. [Abstract] [Full-text]
9. Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells.
   Ann Hematol, 87(3): 195-203. [Abstract] [Full-text]
10. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    J Clin Oncol, 26(4): 577-84. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.